Stephen M Ansell MD PhD

PubMed

• Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
  Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
  Blood. 2025-04-03
• Predictors of Transplant Regret: A Case-Control Study Nested Within a Prospective Cohort of HSCT Recipients.
  Janae L Kirsch, James R Cerhan, William J Hogan, Holly C Edwards, Christi A Patten
  Cancer Medicine. 2025-04-01
• 1 citations
  Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States.
  David J Fei-Zhang, Erik Wu, Alexander V Stanisic, Lifang Hou, Leonidas C Platanias
  Blood Advances. 2025-03-25

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells  
  Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology

Abstracts/Posters

• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
  Stephen M Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
  Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Bridging the Translational Divide: The Role of the PhD 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib for the Treatment of Bing-Neel Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tigit Expression Defines a Subset of Activated Treg Cells with Prognostic Relevance in Follicular Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tumor Immune Interactions in Lymphoid Malignancies 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review 
  Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013
• 9th Annual Mayo Clinic Hematology Review 
  Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 1/28/2012
• Join now to see all